Is Novo Nordisk Stock a Buy?
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
Novo Nordisk high dose weight loss data ‘a double edged sword,’ says BofA
After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...
24/7 Wall St1d
Novo Nordisk A/S
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
pharmaphorum12d
Novo Nordisk asks FDA not to allow GLP-1 compounding
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...
Novo Nordisk: STEP UP Trial Achieves Primary Endpoint - Quick Facts
Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...
El País in English8h
What are the limits in the fight against obesity? Ozempic owner disappoints the market
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...
Hosted on MSN21h
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing ...